by Rakovina Therapeutics | Feb 4, 2026 | Uncategorized
DOWNLOAD Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field. Expanded Opportunity:...
by Rakovina Therapeutics | Jan 28, 2026 | Uncategorized
Proposed $1.0 million Convertible Debenture and concurrent $600,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets ExecutionCurrent Convertible Debenture Maturity Extended; Further...
by Rakovina Therapeutics | Jan 8, 2026 | Uncategorized
DOWNLOAD Vancouver, British Columbia, January 8, 2026 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in...
by Rakovina Therapeutics | Dec 22, 2025 | Uncategorized
DOWNLOAD Vancouver, British Columbia, December 17, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that...
by Rakovina Therapeutics | Dec 16, 2025 | Uncategorized
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies Vancouver, British Columbia, December 10, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a...
by Rakovina Therapeutics | Dec 2, 2025 | Uncategorized
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, December 1, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer...